Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation

Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model... Development of portal hypertension (PHT) is a central prognostic factor in patients with cirrhosis. Circulating microparticles (MPs) are released by hepatocytes in a caspase-dependent manner, are increased in circulation of patients with cirrhosis, and contribute to PHT via induction of impaired vasoconstrictor responses. Here, we tested the hypothesis that emricasan, a pan- caspase inhibitor, ameliorates PHT and reduction in release of MPs. We used a short-term and long-term protocol following common bile-duct ligation (BDL) in C57BL/6 mice (10 and 20 days, respectively). Mice were treated daily via intraperitoneal injection with 10 mg/kg/day of emricasan or placebo. Circulating MP levels were analyzed using flow cytometry and function via ex vivo angiogenesis assays. In contrast to BDL-placebo group, nearly all BDL-emricasan-treated mice survived after long-term BDL. Assessment of portal pressure showed a significant increase in BDL-placebo mice compared to sham-placebo mice. In contrast, BDL-emricasan mice had significantly lower levels of portal pressure compared to BDL-placebo mice. Although emricasan treatment resulted in a decrease in fibrosis, the changes did not reach statistical significance, suggesting that the effects on PHTare at least in part independent of the anti-fibrotic effects of the drug. Following short-term BDL, hepatocellular cell death as well as liver fibrosis http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Molecular Medicine Springer Journals

Emricasan, a pan-caspase inhibitor, improves survival and portal hypertension in a murine model of common bile-duct ligation

Download PDF
9 pages

Loading next page...
 
/lp/springer_journal/emricasan-a-pan-caspase-inhibitor-improves-survival-and-portal-n1JdMapL2z
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Biomedicine; Molecular Medicine; Human Genetics; Internal Medicine
ISSN
0946-2716
eISSN
1432-1440
DOI
10.1007/s00109-018-1642-9
Publisher site
See Article on Publisher Site

Abstract

Development of portal hypertension (PHT) is a central prognostic factor in patients with cirrhosis. Circulating microparticles (MPs) are released by hepatocytes in a caspase-dependent manner, are increased in circulation of patients with cirrhosis, and contribute to PHT via induction of impaired vasoconstrictor responses. Here, we tested the hypothesis that emricasan, a pan- caspase inhibitor, ameliorates PHT and reduction in release of MPs. We used a short-term and long-term protocol following common bile-duct ligation (BDL) in C57BL/6 mice (10 and 20 days, respectively). Mice were treated daily via intraperitoneal injection with 10 mg/kg/day of emricasan or placebo. Circulating MP levels were analyzed using flow cytometry and function via ex vivo angiogenesis assays. In contrast to BDL-placebo group, nearly all BDL-emricasan-treated mice survived after long-term BDL. Assessment of portal pressure showed a significant increase in BDL-placebo mice compared to sham-placebo mice. In contrast, BDL-emricasan mice had significantly lower levels of portal pressure compared to BDL-placebo mice. Although emricasan treatment resulted in a decrease in fibrosis, the changes did not reach statistical significance, suggesting that the effects on PHTare at least in part independent of the anti-fibrotic effects of the drug. Following short-term BDL, hepatocellular cell death as well as liver fibrosis

Journal

Journal of Molecular Medicine – Springer Journals

Published: May 5, 2018

References

  • Changes in hospital admissions and mortality for complications of cirrhosis: implications for clinicians and health systems
    Ho, SB; Matheny, ME; Schnabl, BE
  • Evolving insights in the pathophysiology of complications of cirrhosis: the farnesoid X receptor (FXR) to the rescue?
    Laleman, W; Trebicka, J; Verbeke, L
  • Biological properties of extracellular vesicles and their physiological functions
    Yanez-Mo, M; Siljander, PR; Andreu, Z; Zavec, AB; Borras, FE; Buzas, EI; Buzas, K; Casal, E; Cappello, F; Carvalho, J
  • Extracellular vesicles released by hepatocytes from gastric infusion model of alcoholic liver disease contain a MicroRNA barcode that can be detected in blood
    Eguchi, A; Lazaro, RG; Wang, J; Kim, J; Povero, D; Willliams, B; Ho, SB; Starkel, P; Schnabl, B; Ohno-Machado, L
  • Alcohol stimulates macrophage activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles
    Verma, VK; Li, H; Wang, R; Hirsova, P; Mushref, M; Liu, Y; Cao, S; Contreras, PC; Malhi, H; Kamath, PS; Gores, GJ; Shah, VH
  • Abnormal plasma microparticles impair vasoconstrictor responses in patients with cirrhosis
    Rautou, PE; Bresson, J; Sainte-Marie, Y; Vion, AC; Paradis, V; Renard, JM; Devue, C; Heymes, C; Letteron, P; Elkrief, L
  • The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse
    Canbay, A; Feldstein, A; Baskin-Bey, E; Bronk, SF; Gores, GJ
  • The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
    Barreyro, FJ; Holod, S; Finocchietto, PV; Camino, AM; Aquino, JB; Avagnina, A; Carreras, MC; Poderoso, JJ; Gores, GJ
  • Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis
    Witek, RP; Stone, WC; Karaca, FG; Syn, WK; Pereira, TA; Agboola, KM; Omenetti, A; Jung, Y; Teaberry, V; Choi, SS; Guy, CD; Pollard, J; Charlton, P; Diehl, AM
  • Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis
    Anstee, QM; Concas, D; Kudo, H; Levene, A; Pollard, J; Charlton, P; Thomas, HC; Thursz, MR; Goldin, RD
  • Death receptor-mediated cell death and proinflammatory signaling in nonalcoholic steatohepatitis
    Hirsova, P; Gores, GJ
  • Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury
    Baskin-Bey, ES; Washburn, K; Feng, S; Oltersdorf, T; Shapiro, D; Huyghe, M; Burgart, L; Garrity-Park, M; Vilsteren, FG; Oliver, LK
  • Differential regulation of inflammation and apoptosis in Fas-resistant hepatocyte-specific Bid-deficient mice
    Lazic, M; Eguchi, A; Berk, MP; Povero, D; Papouchado, B; Mulya, A; Johnson, CD; Feldstein, AE
  • Caspase inhibitors for the treatment of liver disease: friend or foe?
    Woolbright, BL; Ding, WX; Jaeschke, H
  • Promising therapy candidates for liver fibrosis
    Wang, P; Koyama, Y; Liu, X; Xu, J; Ma, HY; Liang, S; Kim, IH; Brenner, DA; Kisseleva, T
  • Microparticles release by adipocytes act as “find-me” signals to promote macrophage migration
    Eguchi, A; Mulya, A; Lazic, M; Radhakrishnan, D; Berk, MP; Povero, D; Gornicka, A; Feldstein, AE
  • Circulating extracellular vesicles with specific proteome and liver microRNAs are potential biomarkers for liver injury in experimental fatty liver disease
    Povero, D; Eguchi, A; Li, H; Johnson, CD; Papouchado, BG; Wree, A; Messer, K; Feldstein, AE
  • Lipid-induced signaling causes release of inflammatory extracellular vesicles from hepatocytes
    Hirsova, P; Ibrahim, SH; Krishnan, A; Verma, VK; Bronk, SF; Werneburg, NW; Charlton, MR; Shah, VH; Malhi, H; Gores, GJ